Floatz logo

Tovorafenib

RAF1 Gene Amplification

Day One Biopharmaceuticals, Inc.Small moleculePhase 2Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the RAF1 Gene Amplification cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Tovorafenib is also rated in:

MAP Kinase Family Gene MutationDormant
CC
Indicative ·
47 / 100
View asset →
pilocytic astrocytomaDormant
CC
Indicative ·
47 / 100
View asset →
RAF MutationDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →